PubMed HealthSearch

PubMed · 9007797

Admixture of heparin with urokinase to decrease thrombolysis time and urokinase dose in polytetrafluoroethylene dialysis graft recanalization.

Abstract

PURPOSE: To determine whether the addition of heparin to urokinase during dialysis graft thrombolysis can lower urokinase dose and shorten procedure time. PATIENTS AND METHODS: Patients who underwent dialysis graft thrombolysis during an 18-month period were studied retrospectively. Twenty patients were treated with urokinase alone, and 19 patients were treated with urokinase and heparin. Thrombolysis was performed in the angiography suite by using a crossed-catheter technique. Urokinase was administered directly into the thrombus. In patients receiving heparin, 5,000 IU was added directly to the initial urokinase solution. RESULTS: In patients who received urokinase alone, an average of 750,000 U of urokinase was used, and the average procedure time was 2 hours 42 minutes. When heparin was added, an average of 435,000 U of urokinase was used, and the average procedure time was 2 hours. CONCLUSION: The addition of heparin to urokinase can decrease both urokinase dose and thrombolysis time in the recanalization of dialysis grafts.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D S Harrell, M Kozlowski, M D Katz, S E Hanks. Admixture of heparin with urokinase to decrease thrombolysis time and urokinase dose in polytetrafluoroethylene dialysis graft recanalization.. https://doi.org/10.1016/s1051-0443(96)70761-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Development of a new approach to vascular access.

Three modes of access for hemodialysis (HD) have been available for over 20 years, the native arterial to venous (A-V) fistula, the polytetrafluorethylene (PTFE) graft fistula, and the central venous catheter. Overall, vascular access remains the single most costly source of morbidity and hospitalization in HD patients, indicating a severe need for improvement in this area. A significant contributor to access morbidity is the HD catheter, which protrudes through the skin and is subject to frequent infection. Subcutaneous ports have been developed to overcome this problem with catheters, but their application to HD has been elusive for 2 reasons, the use of a degradable septum that becomes vulnerable to infection with the use of large bore needles and the presence of a nonlinear flow path which produces damage to blood cells and stimulates thrombus formation at the required high flow rates. A new device, the Dialock, overcomes these objections by its use of a mechanical valve that maintains a linear flow path without directly contacting the blood. Results of a pilot study with 23 patients demonstrated a 78% cumulative survival rate after 1 year with a reduced rate of infection compared to catheters and sustained blood flow of 330 ml/min. The device represents a most promising advance in vascular access.

Arteriovenous Shunt, Surgical

Use of vein loops in reconstructive procedures.

The use of a temporary arteriovenous fistula prior to flap harvesting was suggested by Threlfall in 1982 (Threlfall, Aust NZ J Surg 52:182-184, 1982). The basic idea is to use long venous grafts that can be branched side-to-end to a main artery at an easily accessible level using one of the well-established exposures from general vascular surgery. In reconstructive microsurgery, AV-loops are used in limb salvage procedures and in cancer surgery. These patients have often undergone previous surgery and additional radiotherapy. AV-loops facilitate the use of normal recipient vessels out of the zone of injury, or far away from scar or irradiated tissue.

Arteriovenous Shunt, Surgical